Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

March 22, 2021

Study Completion Date

October 1, 2021

Conditions
BlepharospasmBlepharospasm, Benign EssentialCBD
Interventions
DRUG

Cannabidiol Oral Solution [Epidiolex]

100 mg BID for three months Placebo oral solution for three months

Trial Locations (1)

94609

Silkiss Eye Surgery, Oakland

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Benign Essential Blepharospasm Research Foundation

OTHER

collaborator

GW Pharmaceuticals Ltd

INDUSTRY

collaborator

Smith-Kettlewell Eye Research Institute

OTHER

lead

Silkiss Eye Surgery

OTHER